Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV) (AO-LDV)
Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV) in Healthy Subject and Subject Affected by Glaucoma or Retinal Venous Occlusion
The difficulty to measure blood flow in humans is connected with the necessity of using not invasive, reliable and reproducible techniques.
There is several quantitative approaches to study eye blood flow which do not answer all these specifications. The laser doppler velocimetry allows movement speed measures but not vessel diameter. Optical coherence tomography doppler allows a simultaneous diameter and speed of travel (movement) measures, but presents a limited spatial resolution and thereby not easily reproducible vessel diameter measures.
The investigators propose development of a technique allowing a simultaneous diameter and velocity measure of these vessels.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The eye blood flow plays a fundamental role in the eye physiology, insuring the metabolic contributions of various eye tissues, in particular those associated with the vision photochemical processes. Eye blood flow changes are involved in the physiopathology of several frequent eye diseases susceptible to lead to blindness (glaucoma,age-related macular degeneration, venous or arterial occlusions). Numerous systematic pathologies can also alter eye blood flow (diabetes, sleep apnea, arterial high blood pressure, inflammation).
The difficulty to measure blood flow in humans is connected with the necessity of using not invasive, reliable and reproducible techniques.
There is several quantitative approaches to study eye blood flow which do not answer all these specifications. The laser doppler velocimetry allows movement speed measures but not vessel diameter. Optical coherence tomography doppler allows a simultaneous diameter and speed of travel (movement) measures, but presents a limited spatial resolution and thereby not easily reproducible vessel diameter measures.
The investigators propose development of a technique allowing a simultaneous diameter and velocity measure of these vessels.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Grenoble, France, 38043
- Recruiting
- University Hospital Grenoble
-
Contact:
- Florent APTEL, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to give written Informed Consent and to comply with the requirements of the study protocol
- Person affiliated to social security
- Age between 18 and 80 years
- Capable of focusing a target without ocular micro stuttering
- For healthy subject : absence of ocular and systemic pathology and no medical treatment
- For subject with glaucoma : Primitive open-angle glaucoma unilateral or bilateral. Visual field must be considerate as compatible and reliable with campimetric impairment known in glaucoma.
- For subject wih retinal veinous occlusion : Retinal central vein occlusion or branch retinal vein occlusion medically confirmed with an eye fundus exam and fluorescein angiography.
Non-inclusion Criteria:
- Subject mentioned in L1121-5 to L1121-8 article of French Health Code : pregnant women, women capable of child bearing without contraceptive measures, under-age subject, subject under juridic protection or not able to give informed consent, subject deprived of liberty
- Any systemic medication with action on intraocular pressure such as sympathomimetic and beta blocker
- Hypersensitivity to tropicamide or its derivatives or to any eye drops excipients
- Subject who do not want to take part to the study
- Subject participating to another clinical trial
- Subject who can't come back for follow up visits
- Subject with lenses and who can't stop wearing them for the study protocol
- Close or narrow anterior chamber angle
- For healthy subject : Ametropia > 3 diopter, subject with non evolutive or evolutive ocular pathology
- For subject with glaucoma : Ametropia > 3 diopter, secondary glaucoma, closed angle glaucoma, isolated intraocular hypertonia, eye surgery within 3 months before the beginning of the study, trabeculoplasty, filtration surgery, associated evolutive or non-evolutive ocular pathology
- For subject with retinal veinous occlusion : Ametropia > 3, associated evolutive or non-evolutive ocular pathology, patient already treated with intravitreal injection with anti-VEGF or dexamethasone implant (no older than 4 months)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Healthy subjects
120 healthy subjects in the first session and 30 in the second Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
|
Fluxometry measure while subject is sitting in front of the optic adaptative camera
|
|
Experimental: Glaucoma
60 subjects with glaucoma Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
|
Fluxometry measure while subject is sitting in front of the optic adaptative camera
|
|
Experimental: Retinal vein occlusion
80 subjects with retinal vein occlusion including 40 with peripheric occlusion and 40 with central occlusion Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
|
Fluxometry measure while subject is sitting in front of the optic adaptative camera
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of total retinal blood flow in healthy subject
Time Frame: Day 0, Day 30 to Day 60
|
Total retinal blood flow measurement in healthy subject at rest
|
Day 0, Day 30 to Day 60
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Repeatability and reproducibility of retinal blood flow measures intra and inter session
Time Frame: Day 0, Day 30 to Day 60
|
Coefficient of variation for Repeatability and Reproducibility (3 measures session every 5 minutes on the same day, repeated one or two months after)
|
Day 0, Day 30 to Day 60
|
|
Change of retinal blood flow in different ages subjects
Time Frame: Day 0, Day 30 to Day 60
|
Total retinal blood flow measurement in different ages subjects
|
Day 0, Day 30 to Day 60
|
|
Evaluation of the relation between retinal blood flow and vessel diameter
Time Frame: Day 0, Day 30 to Day 60
|
Retinal blood flow and diameter of principal vessels coming from the optic disc
|
Day 0, Day 30 to Day 60
|
|
Measure retinal blood flow in subject with glaucoma and compare results with healthy subjects
Time Frame: Day 0
|
Total retinal blood flow measured in subjects with glaucoma and age- and sex-matched healthy subjects
|
Day 0
|
|
Measure retinal blood flow in subject with retinal vein occlusion and compare results with measurements made in ipsilateral non pathogenic vessels, controlateral vessels and healthy subjects.
Time Frame: Day 0, Month 1, Month 2, Month 3, Month 6
|
Total blood flow compare to the controlateral eye and healthy subject data
|
Day 0, Month 1, Month 2, Month 3, Month 6
|
|
Retinal blood flow evaluation after 1, 2 and 3 months after the inclusion of subject with retinal vein occlusion
Time Frame: Day 0, Month 1, Month 2, Month 3
|
Partial retinal blood flow in a occluded temporal vein compare to a healthy ipsilateral temporal vein
|
Day 0, Month 1, Month 2, Month 3
|
|
Retinal blood flow evaluation after 1, 2, 3 and 6 months after intravitreal injection of aflibercept in subject treated for macular oedema as a complication of retinal vein occlusion
Time Frame: Day 0, Month 1, Month 2, Month 3, Month 6
|
Retinal blood flow evolution will be evaluated regarding macular oedema and retinal ischaemia occurence
|
Day 0, Month 1, Month 2, Month 3, Month 6
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Florent Aptel, PhD, University Hospital, Grenoble
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-A01353-44
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.